Mount Sinai researchers have confirmed for the first time that a simple blood test called a liquid biopsy may be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure. His study was published in Journal of Experimental and Clinical Cancer Research in June.
Liquid biopsies test for biomarkers of PD-L1, a protein and target for a type of immunotherapy called checkpoint inhibitors, which help the patient’s immune system attack and kill cancer cells. This study showed that testing the blood of lung cancer patients for PD-L1 biomarkers improved response and survival for lung cancer patients compared to testing for PD-L1 in tissue from a lung cancer biopsy. Made more accurate predictions, the current standard of care.
The biomarker in the blood, named EV PD-L1, comes from extracellular vesicles, which are particles released from tumor cells. The reduction of PD-L1 in extracellular vesicles in the blood may therefore become a useful test to predict which patients with non-small-cell lung cancer may benefit from immunotherapy.
Senior author Christian Rolfo, MD, PhD, MBA, Professor of Medicine (Hematology), said, “These results will have implications in the search for biomarkers to predict immunotherapy outcome in lung cancer patients as no reliable biomarkers are yet available.” have been found.” and Medical Oncology) at the Icahn School of Medicine at Mount Sinai, associate director of clinical research at the Center for Thoracic Oncology at The Tisch Cancer Institute, and president of the International Society of Liquid Biopsy. “If validated in large prospective cohorts of patients, as we are working on now, this protein could be used for tissue PD-L1 as the standard of care in patients receiving immunotherapy in these and other types of tumor patients.” may complement or substitute, especially because it is minimally invasive and can be repeated across treatments, by being able to detect changes in the tumor in real time during the course of treatment.”
Researchers collected blood samples from two groups of 33 and 24 patients with non-small-cell lung cancer who received immune-checkpoint inhibitors before and after the ninth week of treatment. They also included a group of 15 patients receiving chemotherapy as a control. Extracellular vesicles were isolated from blood samples and protein expression of PD-L1 was measured at both time points in each group. The researchers also measured imaging scans of patients’ tumors before treatment and evaluated them with an innovative imaging technique called radiomics to create a complete model for predicting immunotherapy response.
Doctor. Led by Rolfo, the study involved a collaboration of experts in radiomics and medical oncology from the United States, Mexico and Italy.
material provided by Mount Sinai Hospital / Mount Sinai School of Medicine, Note: Content can be edited for style and length.